916 related articles for article (PubMed ID: 29095069)
1. Effects of tryptophan depletion on selective serotonin reuptake inhibitor-remitted patients with obsessive compulsive disorder.
Hood SD; Broyd A; Robinson H; Lee J; Hudaib AR; Hince DA
J Psychopharmacol; 2017 Dec; 31(12):1615-1623. PubMed ID: 29095069
[TBL] [Abstract][Full Text] [Related]
2. Effects of acute tryptophan depletion in serotonin reuptake inhibitor-remitted patients with generalized anxiety disorder.
Hood SD; Hince DA; Davies SJ; Argyropoulos S; Robinson H; Potokar J; Nutt DJ
Psychopharmacology (Berl); 2010 Feb; 208(2):223-32. PubMed ID: 19936713
[TBL] [Abstract][Full Text] [Related]
3. Lack of effects on core obsessive-compulsive symptoms of tryptophan depletion during symptom provocation in remitted obsessive-compulsive disorder patients.
Berney A; Sookman D; Leyton M; Young SN; Benkelfat C
Biol Psychiatry; 2006 May; 59(9):853-7. PubMed ID: 16213470
[TBL] [Abstract][Full Text] [Related]
4. Tryptophan depletion in patients with obsessive-compulsive disorder who respond to serotonin reuptake inhibitors.
Barr LC; Goodman WK; McDougle CJ; Delgado PL; Heninger GR; Charney DS; Price LH
Arch Gen Psychiatry; 1994 Apr; 51(4):309-17. PubMed ID: 8161291
[TBL] [Abstract][Full Text] [Related]
5. Tryptophan depletion reverses the therapeutic effect of selective serotonin reuptake inhibitors in social anxiety disorder.
Argyropoulos SV; Hood SD; Adrover M; Bell CJ; Rich AS; Nash JR; Rich NC; Witchel HJ; Nutt DJ
Biol Psychiatry; 2004 Oct; 56(7):503-9. PubMed ID: 15450786
[TBL] [Abstract][Full Text] [Related]
6. Effects of tryptophan depletion on cognitive functioning, obsessive-compulsive symptoms and mood in obsessive-compulsive disorder: preliminary results.
Külz AK; Meinzer S; Kopasz M; Voderholzer U
Neuropsychobiology; 2007; 56(2-3):127-31. PubMed ID: 18259085
[TBL] [Abstract][Full Text] [Related]
7. Serotonin and sensitivity to trauma-related exposure in selective serotonin reuptake inhibitors-recovered posttraumatic stress disorder.
Corchs F; Nutt DJ; Hood S; Bernik M
Biol Psychiatry; 2009 Jul; 66(1):17-24. PubMed ID: 19268914
[TBL] [Abstract][Full Text] [Related]
8. Use of factor-analyzed symptom dimensions to predict outcome with serotonin reuptake inhibitors and placebo in the treatment of obsessive-compulsive disorder.
Mataix-Cols D; Rauch SL; Manzo PA; Jenike MA; Baer L
Am J Psychiatry; 1999 Sep; 156(9):1409-16. PubMed ID: 10484953
[TBL] [Abstract][Full Text] [Related]
9. [Efficacy and tolerability of escitalopram in anxiety disorders: a review].
Pelissolo A
Encephale; 2008 Sep; 34(4):400-8. PubMed ID: 18922243
[TBL] [Abstract][Full Text] [Related]
10. Specificity of serotonin reuptake inhibitors in the treatment of obsessive-compulsive disorder. Comparison of fluvoxamine and desipramine.
Goodman WK; Price LH; Delgado PL; Palumbo J; Krystal JH; Nagy LM; Rasmussen SA; Heninger GR; Charney DS
Arch Gen Psychiatry; 1990 Jun; 47(6):577-85. PubMed ID: 2112374
[TBL] [Abstract][Full Text] [Related]
11. Randomized, Double-Blind, Placebo-Controlled Trial of N-Acetylcysteine Augmentation for Treatment-Resistant Obsessive-Compulsive Disorder.
Costa DLC; Diniz JB; Requena G; Joaquim MA; Pittenger C; Bloch MH; Miguel EC; Shavitt RG
J Clin Psychiatry; 2017 Jul; 78(7):e766-e773. PubMed ID: 28617566
[TBL] [Abstract][Full Text] [Related]
12. Response of symptom dimensions in obsessive-compulsive disorder to treatment with citalopram or placebo.
Stein DJ; Andersen EW; Overo KF
Braz J Psychiatry; 2007 Dec; 29(4):303-7. PubMed ID: 18200396
[TBL] [Abstract][Full Text] [Related]
13. Selective serotonin reuptake inhibitors, and serotonin and norepinephrine reuptake inhibitors for anxiety, obsessive-compulsive, and stress disorders: A 3-level network meta-analysis.
Gosmann NP; Costa MA; Jaeger MB; Motta LS; Frozi J; Spanemberg L; Manfro GG; Cuijpers P; Pine DS; Salum GA
PLoS Med; 2021 Jun; 18(6):e1003664. PubMed ID: 34111122
[TBL] [Abstract][Full Text] [Related]
14. Fluvoxamine combination therapy with tropisetron for obsessive-compulsive disorder patients: A placebo-controlled, randomized clinical trial.
Shalbafan M; Malekpour F; Tadayon Najafabadi B; Ghamari K; Dastgheib SA; Mowla A; Shirazi E; Eftekhar Ardebili M; Ghazizadeh-Hashemi M; Akhondzadeh S
J Psychopharmacol; 2019 Nov; 33(11):1407-1414. PubMed ID: 31575326
[TBL] [Abstract][Full Text] [Related]
15. Higher serotonin transporter availability in early-onset obsessive-compulsive disorder patients undergoing escitalopram treatment: A [
Lee J; Kim BH; Kim E; Howes OD; Cho KIK; Yoon YB; Kwon JS
Hum Psychopharmacol; 2018 Jan; 33(1):. PubMed ID: 29210107
[TBL] [Abstract][Full Text] [Related]
16. Sertraline in children and adolescents with obsessive-compulsive disorder: a multicenter randomized controlled trial.
March JS; Biederman J; Wolkow R; Safferman A; Mardekian J; Cook EH; Cutler NR; Dominguez R; Ferguson J; Muller B; Riesenberg R; Rosenthal M; Sallee FR; Wagner KD; Steiner H
JAMA; 1998 Nov; 280(20):1752-6. PubMed ID: 9842950
[TBL] [Abstract][Full Text] [Related]
17. Olanzapine addition in obsessive-compulsive disorder refractory to selective serotonin reuptake inhibitors: an open-label case series.
Weiss EL; Potenza MN; McDougle CJ; Epperson CN
J Clin Psychiatry; 1999 Aug; 60(8):524-7. PubMed ID: 10485634
[TBL] [Abstract][Full Text] [Related]
18. Antipsychotic Augmentation of Serotonin Reuptake Inhibitors in Treatment-Resistant Obsessive-Compulsive Disorder: An Update Meta-Analysis of Double-Blind, Randomized, Placebo-Controlled Trials.
Dold M; Aigner M; Lanzenberger R; Kasper S
Int J Neuropsychopharmacol; 2015 May; 18(9):. PubMed ID: 25939614
[TBL] [Abstract][Full Text] [Related]
19. Risperidone and haloperidol augmentation of serotonin reuptake inhibitors in refractory obsessive-compulsive disorder: a crossover study.
Li X; May RS; Tolbert LC; Jackson WT; Flournoy JM; Baxter LR
J Clin Psychiatry; 2005 Jun; 66(6):736-43. PubMed ID: 15960567
[TBL] [Abstract][Full Text] [Related]
20. Depleting serotonin enhances both cardiovascular and psychological stress reactivity in recovered patients with anxiety disorders.
Davies SJ; Hood SD; Argyropoulos SV; Morris K; Bell C; Witchel HJ; Jackson PR; Nutt DJ; Potokar JP
J Clin Psychopharmacol; 2006 Aug; 26(4):414-8. PubMed ID: 16855462
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
